

September 27, 2019

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Scrip code: 532531

The National Stock Exchange of India Limited

Exchange Plaza , Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: STAR

Dear Sirs,

Sub: Press Release

Please find attached Press Release issued by the Company titled:

‘Strides receives USFDA approval for Solifenacin Succinate Tablets’

Thanks & Regards,

For Strides Pharma Science Limited



Manjula Ramamurthy
Company Secretary



Encl: As Above

Strides Pharma Science Limited

(Formerly Strides Shasun Limited)

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India

Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India

Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

info@strides.com; www.strides.com

Strides receives USFDA approval for Solifenacin Succinate Tablets

*Product approval from facility in Alathur
To be marketed by Strides Pharma Inc. in the US market*

Bangalore, September 27, 2019 - Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for **Solifenacin Succinate Tablets, 5 mg and 10 mg** from the United States Food & Drug Administration (USFDA). The product is a generic version of Vesicare Tablets, 5 mg and 10 mg, of Astellas Pharma US, Inc.

According to IQVIA MAT data, the US market for Solifenacin Succinate Tablets, 5 mg and 10 mg is approximately US\$ 820 Mn. The product will be manufactured at Alathur facility in Chennai and will be marketed by Strides Pharma Inc. in the US market.

The company has 102 cumulative ANDA filings with USFDA of which 66 ANDAs have been approved and 36 are pending approval.

About Solifenacin Succinate Tablets

Solifenacin Succinate Tablet is an antispasmodic indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India- Bangalore (two locations), Pondicherry, and Chennai, Singapore, Italy- Milan, Kenya- Nairobi and United States-Florida. The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com

For further information, please contact:

<u>Strides</u> Badree Komandur Executive Director - Finance +91 80 6784 0747 <u>Investor Relations:</u> Kannan. N: +91 98450 54745	<u>PR Consultancy</u> Fortuna PR K Srinivas Reddy: +91 90005 27213 srinivas@fortunapr.com K Priya: +91 95354 25418 priya@fortunapr.com
---	---

Vikesh Kumar: +91 80 6784 0827
Sandeep Baid: +91 80 6784 0791
Email: Sandeep.baid@strides.com

Strides Pharma Science Limited
(Formerly Strides Shasun Limited)
CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17,
Vashi, Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta
Road, Bangalore – 560 076